English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Chemical regulators of epithelial plasticity reveal a nuclear receptor pathway controlling myofibroblast differentiation.

Carthy, J. M., Stöter, M., Bellomo, C., Vanlandewijck, M., Heldin, A., Morén, A., et al. (2016). Chemical regulators of epithelial plasticity reveal a nuclear receptor pathway controlling myofibroblast differentiation. Scientific Reports, 6: 29868.

Item is

Files

show Files

Locators

show

Creators

show
hide
 Creators:
Carthy, Jon M, Author
Stöter, Martin1, Author           
Bellomo, Claudia, Author
Vanlandewijck, Michael, Author
Heldin, Angelos, Author
Morén, Anita, Author
Kardassis, Dimitris, Author
Gahman, Timothy C, Author
Shiau, Andrew K, Author
Bickle, Marc1, Author           
Zerial, Marino1, Author           
Heldin, Carl-Henrik2, Author
Moustakas, Aristidis, Author
Affiliations:
1Max Planck Institute of Molecular Cell Biology and Genetics, Max Planck Society, ou_2340692              
2Max Planck Society, ou_persistent13              

Content

show
hide
Free keywords: -
 Abstract: Plasticity in epithelial tissues relates to processes of embryonic development, tissue fibrosis and cancer progression. Pharmacological modulation of epithelial transitions during disease progression may thus be clinically useful. Using human keratinocytes and a robotic high-content imaging platform, we screened for chemical compounds that reverse transforming growth factor β (TGF-β)-induced epithelial-mesenchymal transition. In addition to TGF-β receptor kinase inhibitors, we identified small molecule epithelial plasticity modulators including a naturally occurring hydroxysterol agonist of the liver X receptors (LXRs), members of the nuclear receptor transcription factor family. Endogenous and synthetic LXR agonists tested in diverse cell models blocked α-smooth muscle actin expression, myofibroblast differentiation and function. Agonist-dependent LXR activity or LXR overexpression in the absence of ligand counteracted TGF-β-mediated myofibroblast terminal differentiation and collagen contraction. The protective effect of LXR agonists against TGF-β-induced pro-fibrotic activity raises the possibility that anti-lipidogenic therapy may be relevant in fibrotic disorders and advanced cancer.

Details

show
hide
Language(s):
 Dates: 2016
 Publication Status: Issued
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Type: -
 Identifiers: eDoc: 732365
Other: 6599
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: Scientific Reports
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: -
Pages: - Volume / Issue: 6 Sequence Number: 29868 Start / End Page: - Identifier: -